Welcome to Bioprocess Online Live – An interactive forum to discuss some of the most important technologies and trends impacting the biotherapeutic space.
Throughout the year we sit down with industry experts to discuss how biopharmaceutical companies are tackling the biggest bioprocess challenges they face in the development and manufacturing of biologic therapies. These discussions often include Q&A sessions with attendees, and each Bioprocess Online Live session is archived and accessible at any time by registered site users.
NAVIGATING ADC MANUFACTURING COMPLEXITY
Understanding Sponsor/Contractor Roles When Producing ADCs
Antibody-Drug Conjugates (ADCs) are a hot and promising commodity, and a ballooning clinical-stage ADC development community is putting stress on both manufacturing capacity, and antibody engineering and conjugation talent. What does this burgeon mean for ADC manufacturin...
BIOPROCESS INTENSIFICATION IN THE REAL WORLD
Bioprocess Intensification In The Real World
The biopharma “literature” is chock-full of big process intensification promises, but what is really achievable?
SINGLE-USE TECHNOLOGIES FOR BIOPROCESSING: AN ESSENTIAL UPDATE
Single-Use Technologies For Bioprocessing
Expert panelist describe the latest in standardization efforts around single-use in biopharma, regulatory considerations, single-use applications, supply security strategies, single-use economics, and more.
From Bench To Big Bio: The Impact Of Scale On Single Use Decisions
BIOPROCESS MANUFACTURING ANALYTICS & CONTROLS: NEXT GEN TECHNOLOGIES
Bioprocess Manufacturing Analytics & Controls: Next Gen Technologies
What analytics technologies, tools, and instruments do leading biopharmaceutical developers consider requisite in the buildout of a modern biologics/ATMP, manufacturing facility?
Next-Gen Sequencing, Mechanistic Modelling, & What's Missing
Does Manufacturing Complexity Warrant Tech Investment, Or Detract From It?
BIOPROCESS R&D: BEGINNING WITH THE END IN MIND
Bioprocess R&D: Beginning With The End In Mind
In a period marked by resource constraints, focusing R&D on the most likely molecules to succeed is paramount. But, how do you do it? On this Bioprocess Online Live event, we explored the most efficient approaches to scalable discovery, molecular screening and assays,...
HOW COMPUTATIONAL BIOLOGY SPEEDS DRUG DISCOVERY, DEVELOPMENT
How Computational Biology Speeds Drug Discovery, Development
Check out this discussion on two approaches to adopting computational technology – do-it-yourself and outsourcing – with two of the most innovative minds in the space, EVQLV’s Andrew Satz and Recursion President and COO Tina Larson.
MRNA UPDATE: BEYOND PROPHYLACTIC VACCINES
mRNA Update: Beyond Prophylactic Vaccines
mRNA-based therapeutics are widely regarded as a “next big thing” in biopharma, but manufacturing them is fraught with complex challenges. Check out this digital event from Bioprocess Online Live featuring a discussion with mRNA process development experts on ...
The Launch Pad: Why Platforms Matter For mRNA Therapeutic Development
Optimizing mRNA Formulations In A Bottlenecked & Bifurcated Supply Chain
RISK REDUCTION IN MRNA THERAPEUTIC DEVELOPMENT
Risk Reduction In mRNA Therapeutic Development
mRNA is at an inflection point. To reach its therapeutic potential in chronic, and even rare, disease applications, some biopharmaceutical manufacturing fundamentals must be addressed.
Risk Reduction In mRNA Therapeutic Development: Meet The Panel
Novel Excipients Versus Active Substances And Inflammatory Response
mRNA, TFF, And Next Steps To Tackle mRNA Therapeutic Challenges
PROCESS DEVELOPMENT FOR A DIVERSE MAB PIPELINE
Process Development For A Diverse mAb Pipeline
Our latest Bioprocess Online Live virtual panel event covered process development advances in a diversifying mAb market (i.e. bi- and tri-specific) with leading experts in the field.
Multi-Specific Antibody Development: What Challenges The Need For Speed?
Maintaining mAb Viability After The Exponential Growth Phase
Maintaining Downstream Quality In Multi-Specific Antibody Manufacturing
Challenges To Developing High Concentration Formulation For Multi-Specific Antibodies
Introducing New Technology To A Multi-Specific Antibody Line
MANUFACTURING THE 3RD BIOLOGICS REVOLUTION
Manufacturing The 3rd Biologics Revolution
NOW ON DEMAND: HDT Bio Chief Scientific Officer Peter Berglund, Ph.D., Codagenix EVP for Oncology Johanna Kaufmann, Ph.D., and Providence Therapeutics President & Chief Technology Officer Robert Georgantas III, Ph.D. share what's next for thera...
Personalized Or Off The Shelf? Differentiated Approaches To Cancer Vaccines
Maintaining Cost Efficiency In A Personalized Oncology World
Shelf Lives & Logistics: Ensuring The Stability Of Therapeutic Cancer Vaccines
SURGE MANUFACTURING FOR BIOPHARMA RESILIENCE
Surge Manufacturing For Biopharma Resilience
Learn what surge manufacturing is and how mobility, modularity, single-use, and process train redundancy enable the scale required of biopharmas to meet variable public health demands.
REVOLUTIONARY INCREMENTALISM FUTURE-PROOFING MRNA DRUG MANUFACTURING
Revolutionary Incrementalism: Future-Proofing mRNA Drug Manufacturing
Industry experts share go-to best practices, suggestions, and experiences for prioritizing and streamlining technical operations endeavors to prepare mRNA therapeutics companies for the clinic and, eventually, the commercial market.
"Continuous Improvement:" Defining Your Purification Process & Product Specifications
DATA-DRIVEN CMC FOR PD SPEED, REGULATORY EFFICIENCY
Data-Driven CMC For PD Speed, Regulatory Efficiency
CMC sits at the heart of drug development and delivery efficiency, and it's becoming ever more dependent on a digitized, analytically-driven feedback loop. Veteran biopharma technology and CMC leaders, Brian Kirk, Ph.D. and Blair McNeill, Ph.D., joined Bioprocess Onli...
IND SUCCESS: NAVIGATE THROUGH THE REGULATORY GRAY
IND Success: Navigate Through The Regulatory Gray
Umoja Biopharma VP, Regulatory Affairs Helen Kim and NDA Partners' Expert Consultant Daniela Drago dig into the most common reasons for clinical holds, offer tips for avoiding and addressing them, and share best practices and resources for IND preparation in...
MEET OUR HOSTS
Matthew Pillar is chief editor at Bioprocess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies.
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders.
BIOPHARMA PAT: GATEWAY TO CONTINUOUS MANUFACTURING
Can Continuous Biomanufacturing Borrow From Small Molecules?
Applications For PAT And Continuous: Seed Trains & Data Anomalies
Why PAT Is Foundational To Continuous Manufacturing & What Stands In The Way
Methods To Process Intensification, Downstream Challenges In Continuous Manufacturing
How Industry Orgs, Associations Are Supporting Continuous Manufacturing
Sensors & Data: What Feeds Effective Continuous Manufacturing?
LNPS & BEYOND: OPPORTUNITIES IN RNA DELIVERY
Overcoming Regulatory, Safety/Efficacy, And Toxicity Hurdles
REGULATORY HARMONIZATION MEETS CMC REALITIES
Importance Of Cross-Functional Teams In The Regulatory/CMC Dynamic
Understanding Differences Among Global Regulatory Jurisdictions
OVERCOMING PLATFORM INEFFICIENCIES IN MAB MANUFACTURING
Connecting Discovery, Development, And mAb Manufacturing Efficiency
CMC, SCALE UP, & THE ROAD TO MRNA REGULATORY APPROVAL
THE NEXT PANDEMIC: BIOPHARMA'S OPPORTUNITIES AND OBLIGATIONS
MRNA MANUFACTURING: BRIGHT FUTURE, BIG CHALLENGES
BIOPROCESS AUTOMATION: TRUTH OR ILLUSION?
UPSTREAM PROCESS INTENSIFICATION: REAL-WORLD RESULTS
GENE & RNA THERAPIES: REGULATORY REQUIREMENTS TAKE SHAPE
VACCINE MANUFACTURING & REGULATORY ADVANCES: RIDING COVID'S COATTAILS
